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Abstract: Multiple-site colonization with Candida spp. is commonly recognized as a risk 
factor for invasive fungal infection in critically ill patients. We carried out a study to 
determine the relationship between Candida colonization and invasive infection in 
neurological patients admitted to an ICU. At admission (T0) and every three days for two 
weeks, different samples (pharynx swab, tracheal secretions, stomach contents, etc.) were 
collected for mycological surveillance. Candida mannan antigen and Candida anti-mannan 
antibodies were assayed. The Colonization Index (CI) and Corrected Colonization Index 
were calculated for each time point. Of all patients 70% was already colonized by Candida 
spp. at T0 and six of them had CI ≥ 0.5. Three patients developed candidemia; they had  
CI ≥ 0.5 before infection. Positive values of Candida mannan antigen and anti-mannan 
antibodies were found only in the patients with candidemia. The sensitivity and specificity 
of the Candida mannan test were 66.6% and 100%, respectively, while the sensitivity and 
specificity of the anti-mannan antibody test were 100%. In accordance with other authors, 
we find the surveillance cultures are useful to monitor the Candida colonization in ICU 
patients. In addition, the sequential observation of anti-mannan antibodies could   
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contribute to early diagnosis of candidiasis more than Candida mannan antigen in 
immunocompetent patients.  




Invasive fungal infections are an important cause of morbidity and mortality in immunocompromised 
subjects such as patients with severe neutropenia or cancer and in patients admitted to ICU, intensive 
care of neonatology or pediatric intensive care units [1–3]. Currently, chemotherapy, intravascular 
catheter, prolonged stays in ICUs, immunosuppressive therapy for organ transplantation, abdominal 
surgery and Candida  colonization are recognized as risk factors for invasive mycoses [4,5]. In 
particular,  Candida colonization, originating from the endogenous flora that develops within the 
gastrointestinal tract, seems to be the first step towards severe infection [6–8]. In fact, during the 
1980s, Wey et al. [9] identified Candida colonization as an independent risk factor for candidemia. 
Actually, multiple-site colonization with Candida spp. is commonly recognized as a major risk factor 
for invasive fungal infection in critically ill patients and the colonization density could be a predictive 
value for the diagnosis of systemic candidiasis [10–12], nevertheless the distinction between 
colonization and infection is often difficult [13]. Although multiple surveillance cultures are often 
performed daily for critically ill patients, the clinical importance of positive Candida spp. cultures is 
difficult to define. Candida colonization is present in 5–15% of patients but it can achieve peaks of  
50–86% and an invasive infection can develop in 5–30% of colonized patients [14,15]. The death risk 
in patients with distinct colonized body sites is similar to patients with proven Candida invasive 
infection [15]. Pittet et al. [16] demonstrated that Candida colonization assessed by systematic 
screening helps to predict infections in critically ill patients. They defined the Colonization Index (CI) 
and the Corrected Colonization Index (CCI); CI value ≥ 0.5 and CCI ≥ 0.4 were considered thresholds 
to distinguish patients with Candida infection [16]. The choice of surveillance samples to evaluate the 
CI and CCI has not been established, but it would be appropriate to use samples in which the isolation 
of fungi is higher (pharynx swab, tracheal aspirate, rectal swab, etc.). This prospective study aimed at 
evaluating the relationship between Candida colonization and invasive infection in neurosurgical 
patients admitted to an ICU. Moreover, the usefulness of Candida mannan antigen and Candida  
anti-mannan antibodies as markers of infection was also analyzed. 
2. Materials and Methods 
This study was carried out in the Intensive Care Unit of the University Hospital of Southern Italy 
(UHSI) during January–December 2008. UHSI is a 1300-bed teaching hospital with about 500 
admissions per year to the ICU. Int. J. Mol. Sci. 2011, 12 7040 
 
The eligible patients were neurosurgical patients of age >18 years, admitted to the ICU because of 
traumatically or post-operative complications and without documented Candida infection at 
admission. Patients who stayed in the ICU for <7 days were excluded from the study.  
A total of 51 patients met the criteria for inclusion and were prospectively observed for our study. 
At admission (T0) to the ICU and every three days for 2 weeks (T3, T6, T9, T12, T15) the 
following samples were collected for mycological surveillance: pharynx swab, tracheal secretions, 
stomach contents, rectal swab, armpit skin swab, urine, blood, serum for Candida mannan antigen and 
Candida anti-mannan antibodies determination.  
At each time interval, the CI and CCI were calculated.  
The study was approved by the Ethics Committee of Hospital and informed consent was obtained 
from the patients or their representative. 
2.1. Microbiological Methods  
Every biological specimen was cultured on Sabouraud dextrose agar with 0.05% chloramphenicol 
(Oxoid S.p.A.) and chromogenic medium plates (CHROMagar TM Candida Medium, Becton 
Dickinson, Germany) to identify polymicrobial cultures. All plates were incubated at 36 °C (±1) and 
the cultures were examined daily for growth for up to six days before declaring them negative.   
Blood cultures were performed using a lyses centrifugation system (Isolator
® DuPont Co. 
Wilmington–Delaware). The isolates were identified by analysis of biochemical patterns using the ID 
32C and Vitek II systems (bioMérieux, France). 
The serum was frozen at −20 °C and once a week Candida  mannan antigen and anti-mannan 
antibodies were quantified. 
The detection of Candida mannan antigen was measured using a Platelia ELISA system (Platelia
® 
Candida Ag EIA; BIO-RAD, France) according to the manufacturer’s instructions. The cut-off values 
recommended by the manufacturer for interpretation of results were ≥0.5 ng/mL as positive, ranging 
from 0.25–0.49 ng/mL as intermediate and <0.25 ng/mL as negative. Candida anti-mannan antibodies 
were measured using the Platelia
® Candida Ab/Ac/Ak EIA (BIO-RAD, France) according to the 
manufacturer’s instructions. The cut-off values for interpretation of results were >10 AU/mL as 
positive, 5–10 AU/mL as intermediate and <5 AU/mL as negative. Each serum was tested in duplicate. 
The antifungal susceptibility of yeast strains responsible for infection was evaluated using the   
E-test method. E-test strips for amphotericin B (AMB), anidulafungin (AND), caspofungin (CSP), 
itraconazole (ITC), posaconazole (PSC), voriconazole (VRC) (concentrations ranging from 0.002 to  
32 mg/L) and for fluconazole (FLC) (from 0.16 to 256 mg/L) were obtained from AB BIODISK 
(Solna, Sweden) The E-test assay was performed on RPMI 1640 agar plates (Biolife, Milan, Italy) 
following the manufacturer’s instructions. The plates were incubated at 35 °C and read after 24 h. The 
Minimal Inhibitory Concentration (MIC) was taken as the drug concentration at which the border of 
the elliptical inhibition zone intersected the scale on the antifungal test strip. The growth of 
microcolonies within this inhibition zone was disregarded. 
Interpretative criteria were those suggested by the Clinical and Laboratory Standards Institute 
(CLSI): AND and CSP, Susceptible ≤  2 mg/L, Non-Susceptible >  2 mg/L; FLC, S  <  8 mg/L, 
Susceptible Dose-Dependent 16–32 mg/L, R > 64 mg/L; ITC, Susceptible ≤ 0.125 mg/L, Susceptible Int. J. Mol. Sci. 2011, 12 7041 
 
Dose-Dependent 0.25–0.5 mg/L, Resistant ≥ 1 mg/L; VRC, Susceptible ≤ 1 mg/L, Susceptible   
Dose-Dependent 2 mg/L, Resistant ≥ 4 mg/L [17]. Interpretive criteria for AMB and PSC have not 
been established; so in accordance with literature data we selected a breakpoint of >1.0 mg/L to define 
an isolate as AMB Resistant and VRC breakpoints were applied to the PSC MIC value [18,19]. 
2.2. Definitions 
Candida colonization was defined as repeated growth of yeasts from at least two different sites. 
According to Pittet’s definitions, the CI was defined as the ratio of the number of distinct non-blood 
body sites colonized by Candida to the total number of body sites cultured. The CCI was defined as 
the product of the CI multiplied by the ratio of the number of distinct body sites showing heavy growth 
to the total of distinct body sites growing Candida [17]. Patients with CI ≥ 0.5 and CCI ≥ 0.4 were 
considered heavily colonized. Patients were considered infected if a positive Candida spp. culture 
from blood or other sites normally sterile was documented. 
2.3. Statistical Investigation 
The data analysis was executed with the statistical software SPSS (Statistical Package for Social 
Sciences). The statistical model used to arrive at the significance of the averages during the study 
period and among the different specimens was the ANOVA model (variance analysis), it allowed to 
calculate the F test and the p value < 0.05. The technique of multiple comparison with the Tukey HSD 
model to analyze the significant differences among groups was used. The tests gave information on 
which pairs of averages were significantly different. 
3. Results  
A total of 51 patients were enrolled, 30 male and 21 female, of median age 58 ± 18 years (range  
18–83 years). They were monitored for 15 days. The more frequent predisposing factors for Candida 
infection were the presence of central venous catheter (100% of patients), antibiotic therapy (80.3%), 
diabetes (21.5%) and corticosteroid therapy (13.7%). None of the patients received antifungal 
prophylaxis or antifungal treatment previous to ICU admission. The SOFA score at admission was on 
average 6.98 ± 2.64.  
3.1. Colonization Index 
Figure 1 shows the percentage of patients with Candida spp. colonization and CI ≥ 0.5 during 
residence in the ICU. Overall, at admission, 70.6% of patients were already colonized and the 
percentage increased progressively to 92% at T15. Twenty-nine patients were colonized by one 
species, 12 by two species; three different Candida species were isolated in one case. Considering the 
species:  C. albicans was isolated in 76.2% of samples collected for mycological surveillance,   
C. glabrata in 23.8%, C. krusei in 19%, C. parapsilosis in 9.5%, C. tropicalis and C. kefyr in 4.7%, 
and C. inconspicua in 2.4%. At T0, 16.6% of colonized patients had CI ≥ 0.5 and this percentage 
increased during the observation period up to 75% at T15. Int. J. Mol. Sci. 2011, 12 7042 
 
Figure 1. Percentage of patients with Candida spp. colonization and Colonization   
Index ≥ 0.5 during the study period. 
 
The colonization trend in each examined body site demonstrates a major colonization in the 
stomach, trachea and pharynx versus skin and urine on each day of observation (Anova analysis,  
F = 7.212; p < 0.003). The CCI mean value was ≥ 0.4 in all observations with the exception of T0.  
The CI media increased progressively during the observation period (Figure 2) (p = 0.003, 95% 
Conf Interval D: 25.5–47.1).  
Figure 2. Colonization Index media observed during the study period. 
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During our study, three patients developed invasive infection by C. albicans on the 12th, 13th and 
15th day, respectively after admission to the ICU; all three patients had CI ≥ 0.5 before candidemia. 
The features of the three patients with candidal bloodstream infection are documented in the   
Table 1. The three C. albicans strains resulted susceptible to tested antifungal drugs: AND range   
0.016–0.03 mg/L; CSP 0.25–1 mg/L; PSC 0.03–0.125 mg/L; VRC 0.008–0.016 mg/L;   
ITC 0.06–0.125 mg/L; FLC 0.125–0.5 mg/L; AMB 0.25–0.5 mg/L. 
Table 1. Features of the three patients with candidal bloodstream infection. 
  Pt 1  Pt 2  Pt 3 
Sex M  F  F 
Age 26  79  52 
Sofa 8  8  8 
WBC  20 × 10
3/mm
3  7.5 × 10
3/mm
3  15 × 10
3/mm
3 
MV (days)  27  50  15 
Admission days in ICU (no.)  36  57  15 
CI (the day of candidemia)  0.5  0.7  0.5 
Mannan Ag  +  ///  + 
Ag Circulation  4 d P  ///  1 d P 
Ab-anti Candida  14.5 UA/mL  12.8 UA/mL  11.20 UA/mL 
Ab Circulation  7 d B  4 d B  5 d B 
Outcome living  died  living 
M = Male; F = Female; MV = Mechanical Ventilation; + = Circulation of mannan Ag; /// = lack of 
mannan Ag; d P = day post candidemia; d B = days before candidemia; CI = Colonization Index at 
the moment of candidaemia. 
3.2. Candida Mannan Antigen and Anti-Mannan Antibodies 
The circulating Candida mannan and anti-mannan antibodies tests resulted negative in all patients 
without invasive infection. In the three infected patients, the anti-mannan antibodies resulted positive 
4, 5 and 7 days earlier than isolation of fungi in blood cultures, respectively. The Candida mannan 
antigen failed as an early marker of infection, becoming positive in two cases 1 and 4 days later than 
blood cultures resulted positive and in one case, it was always negative despite the infection (Table 1). 
In patients with candidemia the sensitivity and specificity of the Candida mannan test were 66.6% 
and 100% respectively, while the sensitivity and specificity of the anti-mannan antibodies tests   
were 100%.  
4. Discussion 
It is well known that ICU patients are at high risk of fungal infection. Among the different risk 
factors Candida colonization is an important one. In our study we observed only immunocompetent 
patients with neurosurgical complications and many of them were already colonized by Candida spp. 
on admission to the ICU, but only 16% had CI ≥ 0.5. The percentage of colonized patients increased 
significantly on the 6th day of their stay in the ICU. The percentage of patients with CI ≥ 0.5 increased 
significantly during the period T0–T15. In contrast, 90% of patients not colonized at T0 remained not 
colonized throughout their stay in the ICU. In this study invasive methods to assess for colonization Int. J. Mol. Sci. 2011, 12 7044 
 
were used such as aspiration of tracheal secretions and stomach contents; stomach and pharynx 
remained the most colonized body sites in the period from T0 to T15. During the observation period 
three patients developed Candida bloodstream infection, they presented CI ≥ 0.5. These results are in 
accordance to data of other researchers that show Candida colonization often precedes an invasive 
fungal infection and that the risk is correlated to CI [6,20]. Dubau et al. [21] demonstrated that 
antifungal prophylaxis in 35 heavily colonized patients (CI ≥ 0.5) could reduce the density of 
colonization, prevent infection and improve prognosis. 
Despite continuing progress, the diagnosis of Candida invasive infection still presents problems 
because the conventional diagnostic is often insensitive and time-consuming. Some procedures (e.g., 
biopsies) require aggressive approaches that are not compatible with the critical conditions of ICU 
patients. Several assays have been developed to help the diagnosis of deep mycoses, among them tests 
for the detection of Candida mannan antigen and anti-mannan antibodies [22–25]. Studies carried out 
on mannan have demonstrated its role as an important modulator of innate and adaptive immunity; 
mannan induces a strong antibody response. The detection of mannan is quite specific for the diagnosis 
of invasive candidiasis, although this technique requires frequent sampling due to the rapid clearance 
of these antigens from the blood. Recent studies have demonstrated good diagnostic efficacy associating 
this assay with the search for anti-mannan antibodies in critical, but not in immunocompromised   
patients [26]. Retrospective studies on serum samples from 130 patients with candidemia and   
150 serum samples from patients without fungemia showed that the combined detection of mannan 
and anti-mannan antibodies can increase specificity and sensitivity in the diagnosis of Candida spp. 
deep infection [27,28].  
In our study all sera of patients without deep Candida infection resulted negative to Candida 
mannan and anti-mannan antibodies tests, while they resulted positive in patients with candidemia. 
Besides, as also noted by other authors [26] we observed an inverse relationship between antigen and 
antibodies levels; in fact anti-mannan antibodies levels increased before notification of yeasts in blood 
culture, and mannan antigen resulted positive. 
5. Conclusions 
Some important information can be derived from this study. The use of more invasive methods to 
assess for colonization including gastric and tracheal samples could be very useful to increase the 
probability to meet colonized patients. It is important to underline that, in immunocompetent patients, 
the anti-mannan antibodies levels may increase precociously and mask the circulating Candida 
mannan. The sensitivity of the tests is enhanced by regular serological sampling, thus, detection of 
anti-Candida antibodies could be a useful contribution to early diagnosis of invasive infection, but 
further studies should be undertaken in order to better confirm these data. Further, it is of particular 
interest that CI increases significantly after the six days of ICU stay and consequently Candida 
invasive infection is more likely to occur. At T15, among patients with CI ≥ 0.5 the percentage of 
subjects that developed candidemia exceeded 30%. Thus, our experience suggests that monitoring CI 
could be helpful in identifying patients at risk of invasive fungal infection. In addition, complementing 
this with anti Candida antibodies detection in immunocompetent patients with CI ≥ 0.5 increases the 
positive predictivity for infection allowing an early diagnosis of candidemia.  Int. J. Mol. Sci. 2011, 12 7045 
 
Unfortunately, to date prospective surveillance studies of fungal colonization in the ICU are still 
limited and they use different samples for the mycological follow-up of patients. 
Although further studies are needed to compare, standardize and eventually confirm these data it is 
possible to support that monitoring for colonization with Candida species in patients recovered to ICU 
for >7 days may offer opportunity for early intervention for prevention of candidemia. 
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